Pediatric heart transplantation in the current era
Related Experiment Video
Updated: Jan 21, 2026

Optimization of the Cuff Technique for Murine Heart Transplantation
Published on: June 26, 2020
Laura D'Addese1, Anna Joong2, Michael Burch1
1Cardiology Department, Great Ormond Street Hospital NHS Foundation Trust, London, UK.
Insights
Pediatric heart transplantation (PHTx) outcomes are improving with strategies like ABO incompatible listing. However, international practice variations persist in PHTx management and immunosuppression.
Area of Science:
- Pediatric Cardiology
- Transplantation Medicine
- Immunology
Background:
- Pediatric heart transplantation (PHTx) is a critical treatment for end-stage congenital heart disease and cardiomyopathy.
- Graft survival in PHTx recipients has significantly improved, ranging from 13 to 22 years.
Purpose of the Study:
- To offer an international perspective on the current state of pediatric heart transplantation.
- To review recent advancements and ongoing challenges in PHTx.
Main Methods:
- Review of international registry data and collaborative initiatives.
- Analysis of multicenter studies on PHTx management and outcomes.
Main Results:
- Waitlist survival and long-term outcomes in PHTx are progressively improving.
- Strategies to expand the donor pool include ABO incompatible listing and wider weight ranges.
- Significant international variations exist in listing, donor acceptance, immunosuppression, surveillance, and retransplantation practices.
Conclusions:
- Despite improvements, international practice variations in pediatric heart transplantation require standardization.
- Ongoing research and collaborative efforts are essential for advancing PHTx knowledge and patient care.
- Common morbidities such as infection, rejection, and renal dysfunction necessitate continued monitoring and management strategies.
Purpose Of Review:
To provide an international perspective and current review of pediatric heart transplantation (PHTx).
Recent Findings:
Waitlist survival and long-term outcomes in PHTx continue to improve. Strategies to maximize donor pool utilization include ABO incompatible listing for infants and expanded donor-to-recipient weight ranges. However, there is a high degree of practice variation internationally, from listing strategies and donor acceptance practices to chronic immunosuppression regimens, long-term graft surveillance, and consideration for retransplantation.
Summary:
Common indications for PHTx include end-stage congenital heart disease and cardiomyopathy. Current median graft survival among PHTx recipients ranges from 13 to 22 years. Common morbidities include infection, rejection, renal dysfunction, coronary allograft vasculopathy, and posttransplant lymphoproliferative disease. International registry data, collaborative initiatives to standardize management, and multicenter studies continue to improve knowledge and advancement of the field.
Related Concept Videos
Electrical Current
Anatomy of the Heart
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Significance of Displacement Current

